Mecamylamine ophthalmic - CoMentis

Drug Profile

Mecamylamine ophthalmic - CoMentis

Alternative Names: ATG 003; ATG-3

Latest Information Update: 15 Sep 2015

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator CoMentis
  • Class Eye disorder therapies; Norbornanes; Small molecules
  • Mechanism of Action Nicotinic receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Discontinued Age-related macular degeneration; Diabetic macular oedema

Most Recent Events

  • 30 Sep 2007 Phase-II clinical trials in Diabetic macular oedema in USA (Ophthalmic)
  • 10 Apr 2007 Phase-II clinical trials in Age-related macular degeneration in Brazil (Ophthalmic)
  • 06 Mar 2007 Results from a phase I clinical trial involving healthy volunteers added to the adverse events section
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top